Last Updated: 30/01/2023
Safety, tolerability, immunogenicity and protective efficacy of PfSPZ vaccine and PfSPZ-CVac in Indonesian adults against naturally-transmitted malaria
Objectives
To assess the safety, tolerability, immunogenicity and protective efficacy of PfSPZ Vaccine and PfSPZ-CVac against naturally occurring malaria in 372 healthy Indonesian soldiers aged 18-55 years who will be deployed in malarious eastern Indonesia.
Principal Institution
Principal Investigators / Focal Persons
Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
ClinicalTrials.gov Identifier: NCT03503058
External reference
Thematic Categories
Date
May 2022 — Jul 2023
Funding Details
Sanaria, United States
Grant ID: IDSPZV1
Project Site
